Alzheimer’s Research Takes Unexpected Turn Toward Copper

Copper-Based Drug Cuts Alzheimer’s-Linked Brain Protein by 42% and Improves Spatial Memory in Mice

Mostly associated with with wiring and old pennies, copper is hardly the first topic that comes to mind when thinking about Alzheimer’s disease. But deep inside the brain, copper plays a surprisingly important role, and when its balance goes wrong, the fallout may help drive one of the most devastating diseases on the planet.

A new study out of Australia found that delivering copper into the brains of mice engineered to develop Alzheimer’s-like brain changes reduced levels of soluble amyloid-beta 42 in the cortex by 42% and helped treated mice find the escape target nearly 44% faster on a long-term spatial memory test.

What makes the finding worth paying attention to is how the compound works. Rather than attacking amyloid-beta directly, the way most recent Alzheimer’s drugs do, Cu(ATSM) appears to boost part of the brain’s own disposal system, the biological infrastructure that helps move amyloid out of the brain before it builds up.

That disposal system depends on a protein called P-glycoprotein, or P-gp, which sits in the walls of the brain’s tiny blood vessels and acts as a molecular pump. One of its jobs is to help move amyloid-beta out of the brain and toward the bloodstream, where the body can continue clearing it. In people with Alzheimer’s, P-gp levels at this barrier are measurably lower than normal, which means more amyloid stays in the brain. Boosting that pump is what this study set out to test.

Alzheimer’s Has a Trash-Removal Problem Copper May Help Solve

Published in ACS Chemical Neuroscience, the study used female mice genetically engineered to develop Alzheimer’s-like disease. Female mice were selected because they accumulate amyloid more severely and earlier than males in this model. Starting at eight months of age, the mice received daily oral doses of Cu(ATSM) for eight weeks. By the end of treatment, P-gp levels at the brain’s blood vessel walls were 24% higher in treated Alzheimer’s-model mice than in untreated ones.

Copper itself appears to be the driver. Earlier research by the same team showed Cu(ATSM) triggers a specific cellular signaling pathway that ramps up P-gp production in brain blood vessel cells. In this study, the Alzheimer’s-model mice that received Cu(ATSM) showed a large increase in copper concentration in their brain blood vessels, and that copper increase lined up with higher P-gp levels and the 42% drop in cortical amyloid-beta 42. It is a chain of events the researchers believe runs from copper delivery, to higher P-gp levels, to lower amyloid, though they were careful to note the link remains correlative rather than proven. A separate test designed to directly measure amyloid clearance across the blood-brain barrier came back inconclusive, and the authors said establishing causality will require further work.

That caveat matters. Brain immune cells called microglia may also be contributing to the amyloid reduction through their own cleanup activity, independent of P-gp, and sorting out which mechanisms are doing how much work will require follow-up studies.

Copper-Treated Alzheimer’s Mice Found the Exit 44% Faster on Memory Tests

For the memory tests, the researchers used the Barnes maze, a circular platform with holes around the perimeter where mice must learn and remember the location of an escape route over several days of training. Untreated Alzheimer’s-model mice struggled throughout, taking far longer to find the exit and making far more wrong turns than healthy mice. Mice given Cu(ATSM) did markedly better, reaching the escape hole nearly 44% faster on the final recall test and making fewer errors along the way.

Not every memory test told the same story. Shorter assessments that measure more immediate recall showed no benefit from the treatment. Only the Barnes maze, which tests the kind of sustained, learned spatial memory that erodes early in Alzheimer’s, picked up a difference. That is a meaningful distinction, and one the researchers flagged honestly.

Cu(ATSM) has already been tested in human studies for Parkinson’s disease and ALS, giving researchers some early information on dosing and safety that most experimental Alzheimer’s compounds lack. The researchers did not report obvious toxicity in this study, though they also said future work should include standard organ toxicity tests. Human trials targeting Alzheimer’s have not yet begun, but that existing foundation is part of what makes the compound a credible candidate for the next step.

For years, copper’s relationship with Alzheimer’s has been viewed with suspicion; elevated copper in certain forms has been associated with amyloid aggregation and oxidative stress. More recent evidence muddies that picture, linking higher brain copper to protection against cognitive decline rather than acceleration of it.

A compound that uses copper to boost the brain’s own amyloid disposal system, cut soluble amyloid-beta 42 in the cortex by 42%, and improve long-term spatial memory in an animal model does not resolve that debate. Still, this research does suggest the relationship between copper and Alzheimer’s is far more complicated, and potentially more useful, than it once appeared.

---

Disclaimer: This study was conducted in mice, not humans. Results from animal research do not always translate to people, and this compound has not been tested in clinical trials for Alzheimer’s disease. The findings should be considered preliminary. Always consult a qualified medical professional regarding any health or treatment decisions.

---